Gene test could spare prostate cancer patients from radical surgery

This study looks at whether a genetic test can help decide which men with prostate cancer can safely have a less invasive treatment called focal therapy, which targets only the tumor instead of the whole prostate. Researchers will enroll 130 men and use the test to classify their cancer as low or high risk for coming back. Those with low-risk genetics will get focal therapy, while high-risk patients will be advised to have standard treatments like surgery or radiation. The goal is to see if this personalized approach keeps recurrence rates below 10%.